Cargando…

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients

BACKGROUND AND OBJECTIVE: The immunosuppressant everolimus is increasingly applied in renal transplantation. Its extensive pharmacokinetic variability necessitates therapeutic drug monitoring, typically based on whole-blood trough concentrations (C(0)). Unfortunately, therapeutic drug monitoring tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwart, Tom C., Moes, Dirk Jan A. R., van der Boog, Paul J. M., van Erp, Nielka P., de Fijter, Johan W., Guchelaar, Henk-Jan, Keizer, Ron J., ter Heine, Rob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862213/ https://www.ncbi.nlm.nih.gov/pubmed/32720301 http://dx.doi.org/10.1007/s40262-020-00925-8

Ejemplares similares

Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients
por: Zwart, Tom C., et al.
Publicado: (2022)

Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting
por: Zwart, Tom C., et al.
Publicado: (2021)

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
por: Yin, Anyue, et al.
Publicado: (2019)

Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
por: Yin, Anyue, et al.
Publicado: (2022)

Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
por: Yin, Anyue, et al.
Publicado: (2022)

Model‐Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities
por: Keizer, Ron J., et al.
Publicado: (2018)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients
por: Martial, Lisa C., et al.
Publicado: (2021)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
por: Gerritse, Sophie L., et al.
Publicado: (2022)

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics
por: Meziyerh, Soufian, et al.
Publicado: (2020)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients
por: Reinders, Marlies EJ, et al.
Publicado: (2014)

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
por: Fuchs, Uwe, et al.
Publicado: (2012)

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
por: Schneider, T. C., et al.
Publicado: (2015)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
por: Van Keer, Jan, et al.
Publicado: (2017)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study
por: de Jong, Loek A. W., et al.
Publicado: (2020)

Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study
por: de Jong, Loek A. W., et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?
por: van der Stoep, M. Y. Eileen C., et al.
Publicado: (2022)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
por: de Boer, Silke E., et al.
Publicado: (2022)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
por: Uchida, Junji, et al.
Publicado: (2018)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study
por: Moes, Dirk Jan A. R., et al.
Publicado: (2021)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2ijui0sugasjui3edd87qlhla